Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 8/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13076103 | 0.84 | ESR1 (0.41) | ESR1ACP3TSHRSLC6A2SLC6A4 | |
| SCHEMBL8284261 | 0.84 | ADRA2A (0.37) | ESR1TSHRSLC6A2CYP3A4CYP2D6 | |
| SCHEMBL11628582 | 0.82 | ESR1 (0.42) | ESR1ACP3TSHRSLC6A2SLC6A4 | |
| SCHEMBL24222490 | 0.81 | ADRB1 (0.36) | ESR1CYP2D6CTSA | |
| SCHEMBL8995496 | 0.81 | ESR1 (0.38) | ESR1ACP3SLC6A2SLC6A4CYP3A4 | |
| SCHEMBL24129481 | 0.81 | ALDH1A1 (0.45) | TSHRSLC6A2CYP3A4CYP2D6ACHE | |
| SCHEMBL3956324 | 0.79 | SCN1A (0.43) | ESR1ACP3TSHRCTSA | |
| SCHEMBL11128128 | 0.79 | TDP1 (0.42) | ESR1ACP3TSHRCYP3A4CTSA | |
| SCHEMBL13075570 | 0.78 | TAAR1 (0.37) | SLC6A2SLC6A4CYP3A4CYP2D6SLC6A3 | |
| SCHEMBL8284300 | 0.78 | CYP3A4 (0.39) | TSHRSLC6A2SLC6A4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022139228-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC MATERIAL LAYER | 엘티소재주식회사 | 2022-06-30 | — | — | WO | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | ESR1 4063/4885ACP3 338/4885TSHR 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.